ALBT
Avalon Globocare Corp
$
2.290
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.500
Open
2.500
VWAP
--
Vol
386.69K
Mkt Cap
8.77M
Low
2.250
Amount
--
EV/EBITDA(TTM)
--
Total Shares
11.10M
EV
27.88M
EV/OCF(TTM)
--
P/S(TTM)
2.05
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
Show More
Valuation Metrics
The current forward P/E ratio for Avalon Globocare Corp (ALBT.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Avalon Globocare Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+11.19%
349.80K
Total Revenue
FY2025Q1
YoY :
+131.39%
-2.20M
Operating Profit
FY2025Q1
YoY :
+81.51%
-2.48M
Net Income after Tax
FY2025Q1
YoY :
-23.12%
-1.43
EPS - Diluted
FY2025Q1
YoY :
+96.78%
-1.80M
Free Cash Flow
FY2025Q1
YoY :
+21.27%
19.84
Gross Profit Margin - %
FY2025Q1
YoY :
-2.44%
-427.84
FCF Margin - %
FY2025Q1
YoY :
+63.23%
-709.58
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ALBT News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
09:05:34
Avalon enters distribution agreement with Saga Health for KetoAir
2025-07-14 (ET)
2025-07-14
08:07:13
Avalon announces patent issuance for CAR-T, CAR-NK tech in Hong Kong
2025-06-26 (ET)
2025-06-26
08:10:29
Avalon, Qi enter definitive agreement to co-develop cannabis breathalyzer
Sign Up For More Events
Sign Up For More Events
News
7.5
06-26NASDAQ.COMAvalon GloboCare Corp. Partners with Qi Diagnostics to Develop Cannabis Breathalyzer Technology
7.5
06-26NewsfilterAvalon GloboCare and Qi Diagnostics Enter into Definitive Agreement to Co-Develop Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
3.0
06-17BenzingaTop 2 Real Estate Stocks Which Could Rescue Your Portfolio This Quarter
Sign Up For More News
People Also Watch
LTRY
Lottery.com Inc
1.360
USD
+5.84%
TIRX
Tian Ruixiang Holdings Ltd
1.058
USD
-1.12%
THAR
Tharimmune Inc
1.460
USD
0.00%
PAPL
Pineapple Financial Inc
3.500
USD
-5.15%
SGBX
Safe & Green Holdings Corp
0.603
USD
0.00%
SLRX
Salarius Pharmaceuticals Inc
2.080
USD
+180.68%
RIME
Algorhythm Holdings Inc
2.590
USD
0.00%
CELZ
Creative Medical Technology Holdings Inc
2.650
USD
0.00%
FAQ
What is Avalon Globocare Corp (ALBT) stock price today?
The current price of ALBT is 2.29 USD — it has decreased -22.9 % in the last trading day.
What is Avalon Globocare Corp (ALBT)'s business?
What is the price predicton of ALBT Stock?
What is Avalon Globocare Corp (ALBT)'s revenue for the last quarter?
What is Avalon Globocare Corp (ALBT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Avalon Globocare Corp (ALBT)'s fundamentals?
How many employees does Avalon Globocare Corp (ALBT). have?